secondary efficacy endpoints

Related by string. secondary efficacy endpoint * Secon dary . SECONDARY . Secondary : Secondary Offering . Secondary School . Secondary Schools . Lasalle Secondary School / Efficacy . EFFICACY : primary efficacy endpoint . antimicrobial efficacy . preclinical efficacy / Endpoints . EndPoint . Endpoint : Secondary endpoints include . video conferencing endpoints . Secondary endpoints included * *

Related by context. All words. (Click for frequent words.) 81 secondary endpoints 79 efficacy endpoints 76 primary endpoints 75 secondary endpoint 75 primary efficacy endpoints 75 prospectively defined 75 efficacy endpoint 73 primary endpoint 72 composite endpoint 71 primary efficacy endpoint 70 clinical endpoints 69 Secondary efficacy endpoints 69 secondary efficacy endpoint 69 exploratory endpoints 69 Secondary endpoints 68 Primary endpoints 67 desvenlafaxine succinate 67 pharmacodynamic endpoints 66 MEND CABG II 66 prespecified 66 teriflunomide 66 subgroup analyzes 66 SIMPADICO 66 achieved statistical significance 66 placebo controlled clinical trials 66 pharmacokinetics PK 66 elotuzumab 66 dosage regimens 66 noninferiority 66 viral kinetic 65 dose cohorts 65 elagolix 65 pharmacodynamic 65 STRIDE PD 65 pharmacokinetic PK 65 FOLPI 65 lipid parameters 65 endoscopic remission 65 RE LY ® 65 bosentan 65 Secondary endpoints included 65 lintuzumab 65 virologic response 65 GAMMAGARD 65 XIENCE V PROMUS Stent 65 fosbretabulin 65 SYMMETRY trial 65 dosing cohort 65 evaluable 64 viral kinetics 64 trials RCTs 64 ACCORD Lipid 64 CIMZIA TM 64 dose cohort 64 placebo controlled clinical 64 tanespimycin 64 CIMZIA ™ 64 nab paclitaxel 64 metabolic parameters 64 ATACAND 64 pharmacokinetic parameters 64 DAPT 64 R# #mg BID 64 dose limiting toxicities 64 randomized Phase 2b 64 virological response 64 ACTEMRA TM 64 MoxDuo TM IR 64 ENDEAVOR III 64 rALLy trial 64 APTIVUS r 64 CANCIDAS 64 evaluable subjects 64 PASI scores 64 alvimopan 64 PRIMO CABG 63 evaluable patients 63 EURIDIS 63 galiximab 63 patients evaluable 63 SPIRIT FIRST 63 tolerability 63 Phase Ib clinical 63 dose regimens 63 ANCHOR trial 63 non inferiority 63 certolizumab 63 riociguat 63 pharmacokinetic pharmacodynamic 63 Phase Ib study 63 GFT# 63 low dose cytarabine 63 BENICAR HCT 63 placebo controlled Phase 63 PIX# [002] 63 pertuzumab 63 definite stent thrombosis 63 active comparator 63 pharmacokinetic PK profile 63 cytogenetic response 63 cardiovascular morbidity 63 pain palliation 63 MEND CABG 63 budesonide MMX 63 phase Ib 63 VADT 63 Events MACE 63 undetectable HBV DNA 63 pharmacodynamic PD 63 RSD# oral 63 symptomatic VTE 63 Xanafide 63 TAXUS Stent 63 KRAS status 63 ENDEAVOR II 63 Chemophase 63 bicifadine 63 refractory AML 63 relapsed MM 62 HCV SPRINT 62 HBeAg positive patients 62 morphometric vertebral fractures 62 Kaplan Meier analysis 62 oral FTY# 62 Phase 2b study 62 dosing cohorts 62 brivaracetam 62 vidofludimus 62 SVR# 62 pramlintide metreleptin combination 62 celgosivir 62 indiplon capsules 62 dosing regimens 62 LHRH antagonists 62 remission CR 62 NLX P# 62 genotypic resistance 62 dacetuzumab 62 oral rivaroxaban 62 PRECiSE 62 PREZISTA r 62 melphalan prednisone 62 glufosfamide 62 timepoint 62 APTIVUS 62 Phase Ib II 62 TRITON TIMI 62 Traficet EN 62 RE LY 62 prespecified secondary 62 HbA1c levels 62 placebo controlled trials 62 NATRECOR R 62 Panzem R NCD 62 placebo controlled studies 62 HGS ETR1 62 neoadjuvant 62 placebo controlled Phase III 62 Azixa 62 alvespimycin 62 HCV RESPOND 2 62 tipranavir r 62 INCB# [001] 62 EFAPROXYN 62 MERLIN TIMI 62 virologic failure 62 MAP# 62 GOUT 62 6R BH4 62 mapatumumab 62 NP2 Enkephalin 62 lipid lowering agents 62 INC# 61 tolerability profiles 61 demonstrated statistically significant 61 analgesic efficacy 61 CCyR 61 trastuzumab emtansine T DM1 61 phase IIb 61 docetaxel chemotherapy 61 nonrandomized 61 VELCADE melphalan 61 Pharmacokinetic 61 clevidipine 61 afatinib 61 CIMZIA TM certolizumab pegol 61 subanalysis 61 AZILECT R 61 clinically meaningful improvements 61 abiraterone acetate 61 double blinded placebo 61 BRIM3 61 chlorambucil 61 tapentadol ER 61 canakinumab 61 ponatinib 61 tecarfarin 61 coadministration 61 KRN# 61 Entereg R 61 sustained virological response 61 edoxaban 61 NATRECOR ® 61 rindopepimut 61 demonstrated clinically meaningful 61 CTAP# Capsules 61 tolvaptan 61 complete cytogenetic response 61 HGS ETR2 61 TEAEs 61 angiographic outcomes 61 CCX# 61 confirmatory clinical 61 HBeAg negative patients 61 1mg dose 61 CAMMS# 61 ACR# response 61 nonresponders 61 progression TTP 61 PRIMO CABG2 61 primary hypercholesterolemia 61 EDEMA3 61 diabetic neuropathic pain 61 DLTs 61 insulin detemir 61 ACR# ACR# 61 oral ridaforolimus 61 Phase IIIb 61 ZYBRESTAT fosbretabulin 61 clinically meaningful improvement 61 oblimersen 61 efficacy tolerability 61 TMC# C# 61 peginterferon 61 ancrod 61 virologic 61 serum phosphorous 61 APEX AMI trial 61 timepoints 61 SinuNase TM 61 ascending doses 61 Phase 2a trial 61 GSK# [001] 61 inflammatory biomarkers 61 CR nPR 61 CALGB # [001] 61 CHAMPION PLATFORM 61 complete cytogenetic 61 tipranavir 61 neratinib 61 trospium 61 sUA 61 apremilast 61 Dacogen injection 61 phase IIb clinical 61 TELCYTA 61 liver histology 61 plasma pharmacokinetics 60 SILENOR TM 60 Ophena TM 60 maximally tolerated dose 60 ruboxistaurin 60 oxycodone CR 60 Zerenex 60 phase IIa 60 glycated hemoglobin levels 60 Prostate AdenoCarcinoma Treatment 60 FOLFIRI 60 MoxDuo IR 60 Secondary endpoints include 60 PSN# [002] 60 Pharmacokinetic PK 60 Androxal TM 60 Phase 1a clinical 60 postintervention 60 SILENOR 60 Hyphanox 60 phase IIa clinical 60 NEVO ™ 60 multicentre randomized 60 ruxolitinib 60 favorable pharmacokinetic profile 60 IIIa inhibitor 60 mcg BID 60 PREZISTA r arm 60 preclinical efficacy 60 ADAGIO study 60 vismodegib 60 surrogate endpoint 60 limiting toxicity 60 CARE HF 60 SABCS 60 HORIZONS AMI trial 60 CLARITY study 60 MGd 60 velafermin 60 baseline HbA1c 60 comparator arm 60 dose escalation Phase 60 Pharmacokinetic parameters 60 crizotinib PF # 60 Phase 1b 60 INCB# [003] 60 pharmacokinetic profiles 60 specified secondary endpoints 60 mg/m2 dose 60 multicenter Phase 60 decitabine 60 Montgomery Asberg Depression 60 antiviral efficacy 60 BARI 2D 60 macrovascular events 60 alicaforsen enema 60 Phase #b/#a clinical 60 MGN# 60 irbesartan 60 undetectable HCV RNA 60 CR# vcMMAE 60 virologic responses 60 metastatic CRC 60 rosuvastatin #mg 60 Zemplar Capsules 60 ACTEMRA 60 EOquin TM 60 free survival PFS 60 deforolimus 60 Phase Ib 60 ENDEAVOR IV 60 NO# [002] 60 everolimus eluting stents 60 Doxil ® 60 COPERNICUS 60 Dyloject TM 60 catheter occlusion 60 postoperative chemotherapy 60 BRIM2 60 prucalopride 60 HAMD 60 subcutaneous PRO 60 Amrubicin 60 YERVOY 60 pharmacodynamic effects 60 PS# [001] 60 APPRAISE 60 Pimavanserin 60 rapid virologic response 60 Tarceva TM 60 Phase IIB 60 nonfatal MI 60 pharmacokinetic PK study 60 clinically meaningful 60 migalastat HCl 60 CHAMPION PCI 60 DDP# 60 solifenacin 60 adalimumab 60 Capesaris 60 Phase III HEAT 60 Phase #/#a 60 retinal thickness 60 ToGA 60 mg kg dose 60 Phase 1b trial 60 mcg albinterferon alfa 2b 60 β blockers 60 TAXUS VI 60 adenoma recurrence 60 intermittent dosing 60 sipuleucel T 60 EVIZON 60 ARCOXIA 60 REMINYL ® 60 QTc prolongation 60 DASISION 60 baminercept 60 TAXUS ATLAS 60 fluvastatin 60 sustained virologic response 60 nucleoside naive patients 60 CHARM Added 60 Candesartan 60 iniparib 60 Aurexis 60 NEO3 60 posttreatment 60 teduglutide 60 receptor tyrosine kinase inhibitor 60 pomalidomide 60 serum phosphate levels 60 monotherapy 60 enoximone 60 eplerenone 60 vasomotor symptoms 60 androgen suppression 60 goserelin 60 COMFORT II 59 specified primary endpoint 59 PROMACTA 59 mg BID 59 EGFR HER2 59 mg/m2 cohort 59 #mg BID [003] 59 placebo controlled randomized 59 posaconazole 59 tolerability pharmacokinetics 59 Cloretazine 59 phase IIIb 59 plus ribavirin 59 FOLFOX4 59 safinamide 59 AGILECT R 59 rolofylline 59 Initiated Phase 59 EOquin 59 evaluating REVLIMID 59 quetiapine XR 59 Elitek 59 AEGR 59 mg BID dose 59 pharmacodynamic parameters 59 Virulizin ® 59 mRCC 59 pharmacokinetic characteristics 59 Negative Syndrome 59 Phase #/#a trial 59 prospectively stratified 59 UPLYSO 59 paclitaxel eluting stents 59 therapeutic regimens 59 treatment emergent adverse 59 vicriviroc 59 BENICAR 59 Triolex 59 LCP Tacro ™ 59 Q#IR 59 double blinded randomized 59 ARIXTRA 59 custirsen 59 PCI ExTRACT TIMI 59 sapacitabine 59 Baseline characteristics 59 PEGylated interferon beta 1a 59 PRT# 59 pharmacodynamics PD 59 romiplostim 59 FOLFOX regimen 59 preclinically 59 Telintra 59 LUMINATE 59 dose escalation phase 59 SPIRIT III 59 zileuton 59 Archexin 59 neurologic progression 59 forodesine 59 CRp 59 ongoing Phase 1b 59 unique alkylating agent 59 PEG IFN 59 ARB telmisartan 59 fosamprenavir 59 RRMS patients 59 Multicenter Automatic Defibrillator Implantation 59 oxymorphone ER 59 prospective multicentre 59 carboplatin paclitaxel 59 ascending dose 59 BCIRG 59 Psoriasis Area 59 RE SURGE 59 AzaSite Plus 59 PROSTVAC TM 59 oral prodrug 59 pegylated interferon alfa 2b 59 endothelin antagonists 59 Free Survival PFS 59 mg dose 59 #mg BID [001] 59 mesalamine granules 59 ularitide 59 ABC/3TC 59 serum phosphorus 59 MAGE A3 ASCI 59 Amigal 59 MIRCERA 59 venlafaxine XR 59 Phase IIIb clinical 59 statistical significance p 59 pharmacokinetic studies 59 iclaprim 59 Randomized Evaluation 59 GRAVITAS trial 59 RESIST studies 59 Azedra 59 Bezielle 59 AVADO 59 peginterferon alfa 2b 59 tolerated dose MTD 59 Meta analyzes 59 dose proportionality 59 recurrent GBM 59 achieve statistical significance 59 heavily pretreated 59 ribavirin RBV 59 prospective multicenter randomized 59 AVERROES 59 NSABP B 59 Neuradiab 59 attain statistical significance 59 SPIRIVA HandiHaler 59 boosted protease inhibitor 59 acute coronary syndromes ACS 59 HAART regimens 59 CYCLOSET 59 SYNTAX trial 59 mGluR5 NAM 59 ONTARGET 59 LUX Lung 59 Ereska 59 cannabinor 59 EXPAREL ™ 59 eculizumab therapy 59 TOLAMBA 59 HER2 positive metastatic breast 59 montelukast 59 ganetespib 59 PROactive study 59 ibandronate 59 heavily pretreated patients 59 metastatic castration resistant 59 ORENCIA ® 59 AIM HIGH 59 multicenter placebo controlled 59 elacytarabine 59 IMC A# 59 APEX PD 59 Subgroup analysis 59 MoxDuo 59 #mg QD [001] 59 Tavocept 59 HIV RNA 59 GEM OS2 59 Allovectin 7 ® 59 Pegasys ® 59 Phase 2a clinical 59 demonstrated antitumor activity 59 Afatinib 59 GERD symptom 59 relapsed SCLC 59 chemoradiation 59 blinded randomized placebo controlled 59 CYT# potent vascular disrupting 59 binary restenosis 59 Bicifadine 59 APTIVUS R 59 sirolimus eluting stents 59 EDARBI 59 PEG Interferon lambda 59 CLORETAZINE TM VNP#M 59 NOX E# 59 preclinical pharmacokinetic 59 Pivotal Phase 59 Phase 1a 59 RoACTEMRA 59 non metastatic osteosarcoma 59 PRE SURGE 59 lanthanum carbonate 59 multicenter Phase III 59 LEVADEX 59 micafungin 59 clinically meaningful differences 59 huC# DM4 59 Ozarelix 59 pharmacodynamic properties 59 PXD# 59 Liraglutide Effect 59 Welchol 59 prognostic variables 58 Efficacy endpoints 58 TAXUS IV 58 ADAS Cog 58 VIRAMUNE XR 58 R#/MEM # 58 axitinib 58 registrational trial 58 Phase IIa trial 58 varespladib 58 TRANSFORMS 58 budesonide foam 58 KRAS mutations occur 58 Ocrelizumab 58 Phase IIb trials 58 Hematologic 58 cangrelor 58 dexpramipexole 58 EDEMA3 trial 58 Phase 2a 58 multicenter randomized controlled 58 clinical pharmacology studies 58 INCB# [002] 58 K ras mutations 58 orBec 58 ADHF 58 XL# XL# XL# XL# 58 FASLODEX 58 glycosylated hemoglobin levels 58 Maximum Tolerated Dose MTD 58 #mg dose [002] 58 Phase IIa clinical 58 LEXIVA r 58 EMPOWER ™ 58 valopicitabine 58 Tekamlo 58 antidepressant efficacy 58 comorbid conditions 58 hyperoxaluria 58 phase IIb trial 58 prospective randomized controlled 58 aldosterone antagonist 58 tolerability profile 58 haematologic 58 fasting plasma glucose 58 colesevelam HCl 58 Randomized controlled 58 AGILECT ® 58 direct thrombin inhibitors 58 insulin degludec 58 ataluren 58 BARACLUDE ® 58 atrasentan 58 regorafenib 58 endpoints 58 Elagolix 58 histologies 58 serum concentrations 58 Acute Ischemic Stroke 58 trial evaluating PRX# 58 events AEs 58 TYKERB 58 GLYX 58 LymphoStat B 58 peg interferon 58 A1c levels 58 pioglitazone HCl 58 OMAPRO 58 PEGINTRON TM 58 CRLX# 58 phase IIb study 58 ritonavir boosted 58 vildagliptin 58 rALLy 58 bardoxolone 58 HbA 1c 58 multicenter randomized placebo controlled 58 AZOR 58 multicenter randomized double 58 FOLOTYN 58 Teriflunomide 58 randomized discontinuation trial 58 dyslipidaemia 58 DAVANAT 58 cystinosis patients 58 Fludara 58 ExTRACT TIMI 58 Golimumab 58 sunitinib malate 58 bortezomib refractory 58 mycophenolate mofetil 58 QTinno 58 Phase 2b kidney transplant 58 recurrent glioblastoma multiforme 58 HBeAg seroconversion 58 dirucotide 58 LymphoStat B belimumab 58 4mg/kg 58 sitagliptin 58 ON #.Na 58 Committee IDMC 58 pharmacokinetic equivalence 58 mucosal healing 58 Apoptone 58 opioid naïve 58 laboratory abnormalities 58 hemoglobin A1c levels 58 mITT population 58 registrational 58 febrile neutropenia 58 nilotinib 58 statistical significance 58 novel VDA molecule 58 ROCKET AF 58 TASKi2 58 telaprevir dosing 58 dacarbazine 58 pCR 58 interferon gamma 1b 58 metastatic HRPC 58 Thrombolysis 58 Keppra R 58 Subgroup analyzes 58 CoFactor 58 prespecified criteria 58 sargramostim 58 Zoraxel 58 tumor histology 58 Thorough QT 58 Targretin capsules 58 oral Xeloda 58 efficacy 58 ALVESCO 58 fallopian tube cancers 58 bosutinib 58 recurrent VTE 58 events MACE 58 evaluating Xcytrin 58 AIR CF1 58 prospective randomized multicenter 58 antiangiogenic therapy 58 Phase Ia 58 achieved ACR# 58 NEVO RES 58 TACI Ig 58 #mg/m# [002] 58 RECIST criteria 58 enzastaurin 58 LibiGel Phase III 58 peginesatide 58 erlotinib Tarceva ® 58 aflibercept 58 AVOREN 58 #mg/day [001] 58 ONCONASE R 58 multivariate analyzes 58 paclitaxel carboplatin 58 CBLC# 58 Taxotere ® 58 lymphopenia 58 serum HCV RNA 58 Rating Scale MADRS 58 tocilizumab 58 sirolimus eluting stent 58 Phase 1b clinical trials 58 plus dexamethasone 58 antithrombotics 58 univariate analysis 58 estramustine 58 Phase IIb III 58 pramipexole 58 Vilazodone 58 HIF PHI 58 Zenvia Phase III 58 romidepsin 58 denufosol 58 Corlux 58 ENGAGE AF TIMI 58 cediranib 58 safety tolerability pharmacokinetic 58 Proellex TM 58 Ophena 58 ELACYT 58 periprocedural MI 58 randomized blinded 58 mCRC patients 58 HbA 1c levels 58 REVIVE Diabetes 58 Phase 2b clinical 58 elevated ALT 58 fluoropyrimidine 58 PFO migraine 58 splenectomized patients 58 oral diclofenac 58 Pharmacokinetics PK 58 bortezomib 58 randomized Phase IIb 58 antiarrhythmic drug 58 ABSORB trial 58 Phase III randomized controlled 58 eliglustat tartrate 58 eprotirome 58 divalproex sodium 58 dose titration 58 Polyp Prevention Trial 58 Phase IIa clinical trials 58 randomized Phase III 58 Exelixis compounds 58 follicular NHL 58 dose cytarabine 58 unresectable stage 58 FOSRENOL ® 58 mg QD 58 evaluating tivozanib 58 abacavir lamivudine 58 concurrent chemoradiation 58 TNF antagonist 58 Alocrest 58 FOLFOX6 58 aclidinium 58 partial remissions 58 COPAXONE R 58 tasimelteon 58 Zevalin consolidation 58 darunavir ritonavir 58 OPT CHF 58 liver transplant recipients 58 relapsed MCL 58 pramlintide 58 virological failure 58 Ceplene/IL-2 58 MADIT II 58 randomized multicenter 58 eculizumab 58 virologic breakthrough 58 clinically meaningful efficacy 58 lipid lowering therapies 58 evaluating mipomersen 58 paricalcitol 58 corticosteroid dose 58 IRESSA 58 Canvaxin TM 58 univariate 58 inhibitor RG# 58 administered subcutaneously 58 HMG CoA reductase inhibitors 58 Ostarine 57 Urocortin 2 57 HSCT 57 GetGoal Phase III 57 Flu Cy 57 Oral NKTR 57 mg RDEA# 57 lintuzumab SGN 57 dasatinib 57 plus prednisone 57 Solid Tumors criteria 57 FDA defined valvulopathy 57 relapsed refractory multiple myeloma 57 AIR CF2 57 systemic ALCL 57 lumiliximab 57 TMC# r 57 locoregional recurrence 57 dosing schedules 57 forodesine HCl 57 SCH # 57 MGCD# [002] 57 PF # [001] 57 antipsychotic efficacy 57 SAPHRIS 57 MADRS score 57 EVEREST II 57 AeroLEF 57 rHuPH# 57 concomitant medications 57 tumor xenograft models 57 arzoxifene 57 rNAPc2 57 Zenvia 57 Cloretazine R VNP#M 57 pharmacokinetic profile 57 sunitinib 57 RGB # 57 Phase #b/#a trial 57 motesanib 57 LibiGel ® 57 QTc 57 Nesiritide 57 ILLUMINATE 57 FOLFOX6 chemotherapy regimen 57 favorable tolerability 57 Elocalcitol 57 calcineurin inhibitor 57 Efficacy Results 57 antiepileptics 57 lamotrigine 57 mcg QD 57 tezampanel 57 PEG PAL 57 Valsartan 57 prospective randomized placebo 57 Anturol TM 57 NEUVENGE 57 RECIST Response Evaluation Criteria 57 TBC# 57 protease inhibitor PI 57 Tasimelteon 57 squalamine 57 QNEXA 57 IOP lowering 57 Cimzia TM 57 blood Phe 57 graft dysfunction 57 Raptiva ® 57 GEM OS1 57 muraglitazar 57 phase 2a 57 gout flares 57 immunosuppressive agents 57 caspofungin 57 AZD# 57 platelet reactivity 57 tipranavir ritonavir 57 statistically significant improvement 57 mg doses 57 bepotastine besilate nasal spray 57 Tiotropium 57 zonisamide SR 57 MIRAPEX ER 57 EndoTAG TM -1 57 epoetin alpha 57 TEMSO 57 febuxostat 57 pharmacokinetic 57 Endpoints 57 Aptivus ® 57 lixisenatide 57 DSMB 57 sNDA submission 57 cEVR 57 HuMax EGFr 57 XIENCE V demonstrated 57 octreotide 57 peginterferon alfa 2a #KD 57 SPIRIT IV 57 liver metastases 57 Glufosfamide 57 μg dose 57 selective modulator 57 pharmacodynamic markers 57 lymphoma CTCL 57 XL# SAR# 57 #mg dose [001] 57 antitumor activity 57 adecatumumab 57 GVAX 57 ACR# responses 57 methotrexate monotherapy 57 Xelox 57 NAbs 57 cell lymphoma CTCL 57 YMRS 57 cilengitide 57 Ranolazine 57 Response Evaluation Criteria 57 thromboembolic events 57 Motesanib 57 lispro 57 picoplatin 57 HbA1C levels 57 serum phosphate 57 LCP AtorFen 57 substudy 57 carotid artery stenting CAS 57 alpha 2a 57 Asentar 57 Aflibercept 57 assessing T DM1 57 tumor necrosis 57 azacitidine 57 alagebrium 57 histologically confirmed 57 OADs 57 blind placebo 57 peripheral sensory neuropathy 57 cariprazine 57 Phase IIb clinical 57 doxorubicin docetaxel 57 systemic embolism 57 bupropion SR 57 Clolar ® 57 antithrombotic 57 RCTs 57 anti leukemic 57 unblinded 57 tesmilifene 57 TDF FTC 57 Quinamed 57 plus gemcitabine 57 tiotropium 57 Fibrillex TM 57 TLK# 57 OncoVEX GM CSF 57 telbivudine 57 incontinence episodes 57 HuLuc# 57 REVLIMID lenalidomide 57 docetaxel Taxotere ® 57 EDEMA4 57 Serdaxin 57 HGS# 57 RECORD1 57 randomized controlled Phase 57 salmeterol fluticasone 57 dosing intervals 57 Pivotal Phase III 57 docetaxel Taxotere 57 Major Adverse Cardiac 57 null responder HCV 57 Vectibix monotherapy 57 ACCORD COPD

Back to home page